Shares of Heron Therapeutics Inc (NASDAQ:HRTX) have been assigned a consensus rating of “Buy” from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $46.40.

A number of equities research analysts recently weighed in on HRTX shares. Cowen reaffirmed a “buy” rating and issued a $40.00 target price on shares of Heron Therapeutics in a research note on Wednesday, January 15th. Northland Securities reaffirmed a “buy” rating and issued a $47.00 target price on shares of Heron Therapeutics in a research note on Wednesday, November 13th. Svb Leerink reissued an “outperform” rating on shares of Heron Therapeutics in a research note on Tuesday, November 12th. ValuEngine downgraded shares of Heron Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 4th. Finally, BidaskClub downgraded shares of Heron Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday.

In other Heron Therapeutics news, VP Kimberly Manhard sold 24,000 shares of Heron Therapeutics stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $26.00, for a total transaction of $624,000.00. Following the transaction, the vice president now directly owns 24,000 shares of the company’s stock, valued at $624,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 12.56% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Glassman Wealth Services grew its holdings in shares of Heron Therapeutics by 617.3% in the fourth quarter. Glassman Wealth Services now owns 1,162 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 1,000 shares during the last quarter. Quantum Capital Management bought a new position in shares of Heron Therapeutics in the third quarter worth approximately $53,000. Tobias Financial Advisors Inc. bought a new position in shares of Heron Therapeutics in the fourth quarter worth approximately $69,000. Tower Research Capital LLC TRC bought a new position in shares of Heron Therapeutics in the third quarter worth approximately $100,000. Finally, Quantbot Technologies LP grew its holdings in shares of Heron Therapeutics by 433.3% in the fourth quarter. Quantbot Technologies LP now owns 5,333 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 4,333 shares during the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

HRTX traded down $0.51 on Friday, reaching $21.00. The company had a trading volume of 538,325 shares, compared to its average volume of 1,106,659. The business has a 50 day simple moving average of $22.39 and a 200 day simple moving average of $20.96. The company has a market cap of $1.94 billion, a price-to-earnings ratio of -8.46 and a beta of 1.46. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.51 and a current ratio of 3.76. Heron Therapeutics has a 52-week low of $15.68 and a 52-week high of $28.70.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.15. The business had revenue of $42.62 million for the quarter, compared to the consensus estimate of $34.02 million. Heron Therapeutics had a negative net margin of 140.55% and a negative return on equity of 60.76%. Heron Therapeutics’s quarterly revenue was up 115.4% on a year-over-year basis. During the same period last year, the firm posted ($0.49) earnings per share. As a group, equities research analysts predict that Heron Therapeutics will post -2.41 EPS for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Further Reading: What is the outlook for the FAANG stocks?

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.